IL12RB2 and neoplasm: Consistently, neoplastic immune evasion strategies from IL-12-induced anti-tumor immunity exist, since B cells in various chronic lymphoproliferative disorders may silence the gene for IL-12Rβ2 (Il12rb2) by methylation (Airoldi et al., 2004[5]), which was associated with enhanced tumor-cell survival and proliferation in vivo (Airoldi et al., 2005[6]).